Proteostasis Therapeutics

$0.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-10.68%) Today
+$0.05 (5.43%) As of 5:07 PM EDT after-hours

Why Robinhood?

You can buy or sell PTI and other stocks, options, ETFs, and crypto commission-free!

About PTI

Proteostasis Therapeutics, Inc. Common Stock, also called Proteostasis Therapeutics, is a clinical stage biopharmaceutical company, which engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network. Read More The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Employees
48
Headquarters
Boston, Massachusetts
Founded
2006
Market Cap
52.66M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
456.28K
High Today
$1.04
Low Today
$0.9199
Open Price
$1.02
Volume
488.00K
52 Week High
$10.38
52 Week Low
$0.61

Collections

PTI Earnings

-$0.65
-$0.53
-$0.40
-$0.28
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.